Modality
Peptide
MOA
STINGag
Target
KRASG12C
Pathway
Complement
FLMDDSLE
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
~Aug 2020
→ ~Nov 2021
Phase 2
Feb 2022
→ Feb 2030
Phase 2Current
NCT07230449
2,185 pts·FL
2022-02→2030-02·Terminated
2,185 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-063.9y awayPh2 Data· FL
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Termina…
Catalysts
Ph2 Data
2030-02-06 · 3.9y away
FL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07230449 | Phase 2 | FL | Terminated | 2185 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| RHH-5389 | Roche | Preclinical | RET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |